Zymeworks

Zymeworks completes $8.1 million financing round

Friday, September 23, 2011 11:26 AM

Zymeworks, a privately held biotherapeutics company, has completed a financing round totaling $8.1 million. The financing consists of a follow-on round of institutional investment by CTI Life Sciences Fund, as well as a new investment by Advanced Biotechnologies Venture Fund and investments by several existing private shareholders. Zymeworks will use the proceeds to advance its Azymetric and AlbuCORE platforms, as well as the development of its protein therapeutics pipeline in the areas of cancer, autoimmunity and inflammatory diseases.

More... »




CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs